Difference between revisions of "Frankel AE, et al. Blood (2014) cited as Ref 557 in DOI: 10.1038/s41392-020-0110-5 (Q9820)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 124, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): Activity of SL-401 a targeted therapy directed to interleukin-3 receptor in blastic plasmacytoid dendritic cell neoplasm patients, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | Activity of SL-401 a targeted therapy directed to interleukin-3 receptor in blastic plasmacytoid dendritic cell neoplasm patients (English) | ||
| Property / title: Activity of SL-401 a targeted therapy directed to interleukin-3 receptor in blastic plasmacytoid dendritic cell neoplasm patients (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Frankel AE, et al. Blood (2014) cited as Ref 557 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Frankel AE
0 references
2014
0 references
Blood
0 references
124
0 references
Activity of SL-401 a targeted therapy directed to interleukin-3 receptor in blastic plasmacytoid dendritic cell neoplasm patients (English)
0 references
